Fisher Paul B, Gopalkrishnan Rahul V, Chada Sunil, Ramesh Rajagopal, Grimm Elizabeth A, Rosenfeld Myrna R, Curiel David T, Dent Paul
Departments of Pathology, Neurosurgery and Urology, Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons; New York, New York 1032, USA.
Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S23-37.
An obstacle to effective gene-based cancer therapies is the limited number of cancer-specific growth suppressing and apoptosis-inducing genes. Using a differentiation induction subtraction hybridization (DISH) approach with human melanoma cells, melanoma differentiation associated (mda) genes were isolated that display elevated expression as a function of irreversible growth arrest, cancer reversion and terminal differentiation. This screening paradigm resulted in the cloning of mda-7 in the context of terminal differentiation of human melanoma cells. Based on its structure, chromosomal location, sequence homology and cytokine-like properties, mda-7 has now been renamed IL-24 and classified as a member of the expanding IL-10 cytokine gene family. Expression of mda-7/IL-24 inversely correlates with melanoma progression and administration of mda-7/IL-24 by means of a replication incompetent adenovirus, Ad.mda-7, results in growth suppression and apoptosis in melanoma cells as well as in a broad-spectrum of additional cancer cell types. In contrast, Ad.mda-7 does not elicit deleterious effects in normal cells, including those of epithelial, fibroblast, astrocyte, melanocyte or endothelial origin. Based on these distinctive properties and anti-tumor and anti-angiogenic activities in human tumor xenograft animal models, mda-7/IL-24 has now entered the clinical arena. A Phase I/II clinical trial in patients with advanced carcinomas involving intratumoral administration of mda-7/IL-24 [using a replication incompetent adenovirus; ING241 (Ad.mda-7)] has documented that this gene is safe and well tolerated by patients and a single virus injection elicits apoptosis in a majority of the tumor. Current data suggests that mda-7/IL-24 may function as a dual-acting cytokine in which its normal physiological functions may be related to specific aspects of the immune system and over-expression culminates in cancer-specific apoptosis. This review will provide a prospectus of our current understanding of mda-7/IL-24.
有效的基于基因的癌症治疗面临的一个障碍是癌症特异性生长抑制和凋亡诱导基因数量有限。利用人黑色素瘤细胞的分化诱导消减杂交(DISH)方法,分离出了黑色素瘤分化相关(mda)基因,这些基因随着不可逆生长停滞、癌症逆转和终末分化而表达升高。这种筛选模式导致在人黑色素瘤细胞终末分化的背景下克隆出了mda-7。基于其结构、染色体定位、序列同源性和细胞因子样特性,mda-7现在已被重新命名为IL-24,并被归类为不断扩大的IL-10细胞因子基因家族的成员。mda-7/IL-24的表达与黑色素瘤进展呈负相关,通过无复制能力的腺病毒Ad.mda-7给予mda-7/IL-24,可导致黑色素瘤细胞以及多种其他癌细胞类型的生长抑制和凋亡。相比之下,Ad.mda-7对正常细胞没有有害影响,包括上皮细胞、成纤维细胞、星形胶质细胞、黑素细胞或内皮细胞来源的细胞。基于这些独特特性以及在人肿瘤异种移植动物模型中的抗肿瘤和抗血管生成活性,mda-7/IL-24现已进入临床阶段。一项针对晚期癌症患者的I/II期临床试验,涉及瘤内给予mda-7/IL-24[使用无复制能力的腺病毒;ING241(Ad.mda-7)],已证明该基因对患者是安全且耐受性良好的,单次病毒注射可使大多数肿瘤发生凋亡。目前的数据表明,mda-7/IL-24可能作为一种双效细胞因子发挥作用,其正常生理功能可能与免疫系统的特定方面有关,而过表达最终导致癌症特异性凋亡。本综述将提供我们目前对mda-7/IL-24的理解概述。